

PALM INTRANET

Day: Friday
Date: 1/5/2007
Time: 15:58:56

Inventor Name Search Result

Your Search was:

Last Name = KERWIN First Name = SEAN

			<u> </u>		
Application#	Patent#	Status	Date Filed	Title	Inventor Name
08773398	Not- Issued	163	12/24/1996	RICIN INHIBITORS AND METHODS FOR USE THEREOF	KERWIN, SEAN
09118535	6177280	150	1	RICIN INHIBITORS AND METHODS FOR USE THEREOF	KERWIN, SEAN
09230208	Not Issued	161	01/01/0001	METHODS AND COMPOSTIONS FOR STIMULATING OSTEOBLAST PROLIFERATION AND METHODS FOR SELECTING OSTEBLAST PROLIFERATON STIMULANTS	KERWIN, SEAN
09535460	6562969	150	03/24/2000	RICIN INHIBITORS AND METHODS FOR USE THEREOF	KERWIN, SEAN
60016088	Not Issued	159	06/20/1996	COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF	KERWIN, SEAN
09730893	6689887	150	12/05/2000	INHIBITION OF HUMAN TELOMERASE BY A G- QUADRUPLEX-INTERACTION COMPOUND	KERWIN, SEAN M.
<u>09771016</u>	Not Issued	167	01/25/2001	METAL BINDING DNA INTERACTIVE COMPOUNDS	KERWIN, SEAN M.
09940173	6623930	150	08/27/2001	INHIBITION OF HUMAN TELOMERASE BY A G- QUADRUPLEX-INTERACTION COMPOUND	KERWIN, SEAN M.
<u>10108606</u>	6720344	150	03/27/2002	METHODS AND COMPOSITIONS FOR STIMULATING OSTEOBLAST PROLIFERATION OR TREATING MALIGNANT CELL PROLIFERATION AND METHODS FOR SELECTING OSTEOBLAST PROLIFERATION STIMULANTS	KERWIN, SEAN M.
10720991	Not	30	11/24/2003	UK-1 analogues: methods of	KERWIN, SEAN

	Issued			preparation and use	M.
10775818	Not Issued	161	02/10/2004	Inhibition of human telomerase by a G-quadruplex-interaction compound	
60428379	Not Issued	159	11/22/2002	UK-1 analogues: methods of preparation and use	KERWIN, SEAN M.
08675119	6054442	150	07/03/1996	METHODS AND COMPOSITIONS FOR MODULATION AND INHIBITION OF TELOMERASE IN VITRO	KERWIN, SEAN M.
08808742	5922753	150	02/28/1997	METHODS FOR TREATING BONE DEFICIT CONDITIONS WITH BENZOTHIAZOLE	KERWIN, SEAN M.
08879457	6004939	150	06/20/1997		KERWIN, SEAN M.
<u>09244675</u>	6156763	150	02/04/1999	INHIBITION OF HUMAN TELOMERASE BY A G- QUADRUPLEX-INTERACTION COMPOUND	KERWIN, SEAN M.
<u>09245019</u>	6528517	150	02/04/1999	SYNTHESIS OF QUINOBENZOXAZINE ANALOGUES WITH TOPOISOMERASE II AND QUADRUPLEX INTERACTIONS FOR USE AS ANTINEOPLASTIC AGENTS	KERWIN, SEAN M.
<u>09297188</u>	6649631	150		COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS	KERWIN, SEAN M.
09356303	6908948	150	07/16/1999	NOVEL DNA-CLEAVING ANTITUMOR AGENTS	KERWIN, SEAN M.
09467932	6593306	150	12/21/1999	METHODS FOR MODULATION AND INHIBITION OF TELOMERASE	KERWIN, SEAN M.
60005830	Not Issued	159	10/23/1995		KERWIN, SEAN M.
60073629	Not Issued	159	02/04/1998	INHIBITION OF HUMAN TELOMERASE BY A G- QUARDRUPLEX-INTERACTION COMOUND	KERWIN, SEAN M.
60073658	Not Issued	159	02/04/1998	SOLID PHASE PARALLEL SYNTHESIS OF QUINOBENZOXAZINE ANALOGS FOR USE AS ANTI- NEOPLASTIC AGENTS	KERWIN, SEAN M.

60093112	Not Issued	159		NOVEL DNA-CLEAVING ANTITUMOR AGENTS	KERWIN, SEAN M.
60178082	Not Issued	159		METAL BINDING DNA INTERACTIVE COMPOUNDS	KERWIN, SEAN M.
09533723	6297284	150	03/23/2000		KERWIN, SEAN MICHAEL
09967133	6686345	150	1	DNA-CLEAVING ANTITUMOR AGENTS	KERWIN, SEAN MICHAEL

Inventor Search Completed: No Records to Display.

Search Another:	Last Name	First Name	
	Inventor	sean	earch

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

L2 ANSWER 1 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 26

REF: U.S. Pat. Appl. Publ., 2005004188, 06 Jan 2005

NOTE: thermal, neat; vacuum applied every 20 min. to remove water

vapor

CON: 2 hours, 230 deg C

L2 ANSWER 2 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 5

$$CF_3$$
 CF_3
 CF_3
 CF_3
 CF_3
 CF_3
 CF_3
 CF_3
 CF_3
 CF_3

1. C:282713-83-1,> Butyrolactone

$$\begin{bmatrix} & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\$$

100%

REF: Chemistry Letters, 33(10), 1342-1343; 2004 NOTE: stage 2 - no solvent, solid-state, thermal

CON: STAGE(1) 1 hour, room temperature; 5 minutes, 120 deg C

STAGE(2) 10 minutes, 250 deg C

L2 ANSWER 3 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(43) OF 273

1. Pyridinium chloride

2. HCl, Water

Journal of Medicinal Chemistry, 47(21), 5021-5040; 2004

NOTE: thermal

STAGE(1) 1 hour, 200 deg C; 200 deg C -> room temperature STAGE(2) room temperature CON:

L2ANSWER 4 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(22) OF 268

REF: Bioorganic & Medicinal Chemistry Letters, 14(14), 3799-3802;

2004

CON: reflux

L2 ANSWER 5 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 41

Bioorganic & Medicinal Chemistry Letters, 14(12), 3221-3226; REF:

2004 NOTE: thermal CON: 230 deg C

L2 ANSWER 6 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 32

91%

REF: Bioorganic & Medicinal Chemistry, 10(12), 3997-4004; 2002 NOTE: thermal, no solvent, low pressure CON: 2 hours, 230 deg C

L2ANSWER 7 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(22) OF 78

$$\begin{array}{c|c} \text{Me} & \text{CH}_2 & \text{Me} \\ \hline \\ \text{Ph-C-NH} & \text{Ph-C-NH} \\ \hline \\ \text{O} & \text{O} \end{array}$$

Me
$$CH_2$$
 CH_2 CH_2 Ph

85%

REF: European Journal of Organic Chemistry, (12), 1996-2006; 2002 NOTE: alternative reaction conditions gave lower yield, thermal

L2 ANSWER 8 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(6) OF 29

80%

REF: Bioorganic & Medicinal Chemistry Letters, 11(12), 1545-1548; 2001

L2 ANSWER 9 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

Me Me Me
$$CH_2$$
 CH_2 CH_2

REF: Tetrahedron Letters, 41(42), 8111-8116; 2000 NOTE: thermal key step (180.degree., 24 h); neat

L2 ANSWER 10 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 7

66%

REF: Tetrahedron Letters, 38(2), 199-202; 1997 NOTE: 230.degree.C, 1 h

L2 ANSWER 11 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(30) OF 74

REF: Eur. Pat. Appl., 92136, 26 Oct 1983

L2 ANSWER 12 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(8) OF 14

REF: Zhurnal Organicheskoi Khimii, 18(5), 1075-9; 1982

L2 ANSWER 13 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 36

REF: Journal of Medicinal Chemistry, 20(6), 797-801; 1977

L2 ANSWER 14 OF 14 CASREACT COPYRIGHT 2007 ACS on STN

RX(6) OF 30

REF: Journal of Medicinal Chemistry, 18(1), 53-8; 1975

=>

ANSWER 1 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 26

REF: U.S. Pat. Appl. Publ., 2005004188, 06 Jan 2005

NOTE: thermal, neat; vacuum applied every 20 min. to remove water

vapor

. CON: 2 hours, 230 deg C

L2 ANSWER 2 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 5 CF₃ (step 1)

1. C:282713-83-1,

Butyrolactone

100%

REF: Chemistry Letters, 33(10), 1342-1343; 2004 NOTE: stage 2 - no solvent, solid-state, thermal CON: STAGE(1) 1 hour, room temperature; 5 minutes, 120 deg C STAGE(2) 10 minutes, 250 deg C

L2ANSWER 3 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(22) OF 268

Bioorganic & Medicinal Chemistry Letters, 14(14), 3799-3802; REF:

2004 CON: reflux

L2 ANSWER 4 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 41

. 89%

REF: Bioorganic & Medicinal Chemistry Letters, 14(12), 3221-3226;

2004

NOTE: thermal CON: 230 deg C

ANSWER 5 OF 24 CASREACT COPYRIGHT 2007 ACS on STN L2

RX(4) OF 31

REF: Journal of Heterocyclic Chemistry, 41(2), 247-251; 2004

CON:

STAGE(1) reflux STAGE(2) 24 hours, reflux

L2ANSWER 6 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 40

REF: Bioorganic & Medicinal Chemistry, 12(1), 17-21; 2004

CON: overnight, reflux

L2 ANSWER 7 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 32

91%

REF: Bioorganic & Medicinal Chemistry, 10(12), 3997-4004; 2002.

NOTE: thermal, no solvent, low pressure

CON: 2 hours, 230 deg C

L2 ANSWER 8 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(18) OF 78

81%

REF: European Journal of Organic Chemistry, (12), 1996-2006; 2002 NOTE: alternative reaction conditions gave lower yield, thermal

L2 ANSWER 9 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(6) OF 29

Pyridinium tosylate, Xylene

REF: Bioorganic & Medicinal Chemistry Letters, 11(12), 1545-1548; 2001

L2 ANSWER 10 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(6) OF 17

$$\begin{array}{c|c}
CH_2 \\
C-CH_2-C-CH_2-C-CH_2-C-CH_2
\end{array}$$

$$\begin{array}{c|c}
NH-C-Ph & Ph-C-NH
\end{array}$$

Ph-C-NH
$$CH_2$$
 + CH_2 CH_2

REF: Tetrahedron Letters, 41(42), 8111-8116; 2000 NOTE: thermal key step (180.degree., 24 h); neat

L2 ANSWER 11 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 4

REF: Tetrahedron, 53(2), 457-464; 1997

L2 ANSWER 12 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 7

66%

REF: Tetrahedron Letters, 38(2), 199-202; 1997

NOTE: 230.degree.C, 1 h

L2 ANSWER 13 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 2

REF: Journal of the Chemical Society, Perkin Transactions 2: Physical

Organic Chemistry, (7), 1497-501; 1995

NOTE: thermal

L2 ANSWER 14 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 2

$$\begin{array}{c|c}
 & O \\
 & O \\
 & OH
\end{array}$$
O2
$$\begin{array}{c}
 & N \\
 & O \\$$

REF: Journal of the Serbian Chemical Society, 58(9), 629-39; 1993

NOTE: thermal

L2 ANSWER 15 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 3

REF: Eur. Pat. Appl., 332988, 20 Sep 1989

L2 ANSWER 16 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(16) OF 54

REF: Chemica Scripta, 27(3), 411-16; 1987

L2 ANSWER 17 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(30) OF 74

REF: Eur. Pat. Appl., 92136, 26 Oct 1983

L2 ANSWER 18 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 14

$$\begin{array}{ccc}
& & & & \\
& & & & \\
& & & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & &$$

REF: Zhurnal Organicheskoi Khimii, 18(5), 1075-9; 1982

RX(2) OF 47

REF: Pharmazie, 35(5-6), 285-8; 1980

L2 ANSWER 20 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(3) OF 36

REF: Journal of Medicinal Chemistry, 20(6), 797-801; 1977

L2 ANSWER 21 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(2) OF 12

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

REF: Trudy Instituta - Moskovskii Khimiko-Tekhnologicheskii Institut imeni D. I. Mendeleeva, 86,, 152-4; 1975

L2 ANSWER 22 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(1) OF 6

$$O_2N$$
 O_2N
 O_2N
 O_3N
 O_2N
 O_3N
 O_2N
 O_3N
 O_2N
 O_3N
 O_2N
 O_3N
 O_3N

REF: Indian Journal of Chemistry, 13(7), 652-4; 1975

L2 ANSWER 23 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(6) OF 30

REF: Journal of Medicinal Chemistry, 18(1), 53-8; 1975

L2 ANSWER 24 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

RX(15) OF 98

$$\bigcap_{OH} \bigcap_{NH-C} \bigcap_{NO_2} \bigcap_{$$

REF: Indian Journal of Chemistry, 12(3), 263-9; 1974